Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000217997 | SCV000279905 | uncertain significance | not provided | 2016-02-19 | criteria provided, single submitter | clinical testing | This variant is denoted MSH6 c.792A>C at the cDNA level, p.Glu264Asp (E264D) at the protein level, and results in the change of a Glutamic Acid to an Aspartic Acid (GAA>GAC). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. MSH6 Glu264Asp was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Glutamic Acid and Aspartic Acid share similar properties, this is considered a conservative amino acid substitution. MSH6 Glu264Asp occurs at a position that is conserved across species and is not located in a known functional domain (Kariola 2002, Terui 2013). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether MSH6 Glu264Asp is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. |
Labcorp Genetics |
RCV002516207 | SCV002958848 | benign | Hereditary nonpolyposis colorectal neoplasms | 2022-11-09 | criteria provided, single submitter | clinical testing |